Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery

Next Previous
Trial Profile

A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozuleristide (Primary)
  • Indications Glioma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Blaze Bioscience

Most Recent Events

  • 09 May 2019 According to a Blaze Bioscience media release, results from the study have been published in the peer-reviewed journal Neurosurgery.
  • 09 May 2019 Results presented in a Blaze Bioscience media release.
  • 05 Jun 2018 Results (n=42) evaluating PK parameters in 2 clinical studies (NCT02234297 and NCT02462629) presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top